Osteoporosis :: Aclasta Reclast prevents additional fractures in hip fracture patients with osteoporosis
Results of the first-ever clinical study in patients with osteoporosis who suffered a hip fracture show that a once-yearly infusion of Aclasta®/Reclast® (zoledronic acid 5 mg)[*] reduced the risk of subsequent fractures by 35% compared to patients treated with placebo.